Kaushal Neha, Durmaz Yasemin Yuksel, Bao LeWei, Merajver Sofia D, ElSayed Mohamed E H
‡Department of Internal Medicine, School of Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.
§Macromolecular Science and Engineering Program, University of Michigan, 2300 Hayward Avenue, Ann Arbor, Michigan 48109, United States.
Mol Pharm. 2015 Jul 6;12(7):2406-17. doi: 10.1021/acs.molpharmaceut.5b00114. Epub 2015 May 28.
Rho-GTPases are small GTP-binding proteins that contribute to the epithelial-to-mesenchymal transition by regulating several cellular processes including organization of the actin cytoskeleton, cell motility, transcription, and cell proliferation. Overexpression of RhoC-GTPases (RhoC) in breast cancer has been implicated in poor disease prognosis due to increased cancer cells invasion, migration, and motility, which warranted its consideration as a therapeutic target for inhibiting breast cancer metastasis. Using silencing RNA (siRNA) molecules to knockdown RhoC expression is a promising approach to inhibit breast cancer metastases. However, transforming anti-RhoC siRNA molecules into a viable therapy remains a challenge due to the lack of a biocompatible carrier that can selectively deliver the RNA cargo into breast cancer cells. We report the use of a degradable, pH-sensitive, β-cyclodextrin (βCD)-based polymeric carrier that condenses anti-RhoC siRNA forming "smart" particles. These smart anti-RhoC particles were efficiently internalized, successfully escaped the endosome, and delivered the RNA cargo into the cytoplasm of SUM149 and MDA-MB-231 breast cancer cells. Our results show that anti-RhoC particles used at a low N/P ratio of 2.5/1 suppressed RhoC protein levels by 100% and 90% in SUM149 and MDA-MB-231 cells, respectively. Further, anti-RhoC particles inhibited the invasion, motility, and migration of SUM149 and MDA-MB-231 cells by 40-47%, 57-60%, and 61.5-73%, respectively. Smart particles encapsulating the scrambled siRNA sequence did not affect RhoC protein expression or the invasion, motility, and migration of SUM149 and MDA-MB-231 cells, which indicate the biocompatibility of the polymeric carrier and selectivity of the observed RhoC knockdown. These results collectively indicate the therapeutic potential of smart anti-RhoC particles in arresting the metastatic spread of breast cancer cells.
Rho-GTP酶是一类小的GTP结合蛋白,通过调节包括肌动蛋白细胞骨架组织、细胞运动、转录和细胞增殖在内的多种细胞过程,促进上皮-间质转化。乳腺癌中RhoC-GTP酶(RhoC)的过表达与疾病预后不良有关,因为癌细胞的侵袭、迁移和运动增加,这使得它被视为抑制乳腺癌转移的治疗靶点。使用小干扰RNA(siRNA)分子敲低RhoC表达是抑制乳腺癌转移的一种有前景的方法。然而,由于缺乏能够将RNA货物选择性递送至乳腺癌细胞的生物相容性载体,将抗RhoC siRNA分子转化为可行的治疗方法仍然是一个挑战。我们报告了使用一种可降解的、对pH敏感的、基于β-环糊精(βCD)的聚合物载体,该载体可浓缩抗RhoC siRNA形成“智能”颗粒。这些智能抗RhoC颗粒能够有效地被内化,成功逃离内体,并将RNA货物递送至SUM149和MDA-MB-231乳腺癌细胞的细胞质中。我们的结果表明,以2.5/1的低N/P比使用的抗RhoC颗粒分别使SUM149和MDA-MB-231细胞中的RhoC蛋白水平降低了100%和90%。此外,抗RhoC颗粒分别抑制了SUM149和MDA-MB-231细胞的侵袭、运动和迁移40 - 47%、57 - 60%和61.5 - 73%。包裹乱序siRNA序列的智能颗粒不影响RhoC蛋白表达或SUM149和MDA-MB-231细胞的侵袭、运动和迁移,这表明聚合物载体的生物相容性以及所观察到的RhoC敲低的选择性。这些结果共同表明智能抗RhoC颗粒在阻止乳腺癌细胞转移扩散方面的治疗潜力。